Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Now in its 7th year, our free-to-attend careers event will be held at the Royal Society of Medicine on the 18th February 2026 ...

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix, an emerging, clinical-stage biotech company ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

At Frontiers Health 2025, we caught up with Moredreck Chibi (World Health Organization) and Chrys Herrera (Merck KGaA) after ...

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and ...

A recent scientific preprint published by Paradromics reported that the Connexus implant – a tiny device that is implanted ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access ...

Personalised cell therapy developer Aspen Neuroscience added $115 million to its cash reserves with a Series C that included ...

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint ...

At Frontiers Health 2025, patient advocate Silvia Cerolini (Eyes on the Future) opened the conference by sharing her story of ...